ReviewFrontiers in medicine2026
PET-guided therapy: synergies, strategies, and future directions in external beam radiation therapy and radiopharmaceutical therapy.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron Emission Tomography (PET) has evolved from a purely diagnostic modality into a cornerstone of precision radiation oncology. PET now informs patient selection, target delineation, treatment personalization, and post-therapy evaluation across External Beam Radiation Therapy (EBRT) and Radiopharmaceutical Therapy (RPT). Radiotracers provide quantitative data on tumor biology, heterogeneity, receptor expression, and therapeutic response, enabling a shift from morphology-based to biology-driven oncology. PET-guided therapy is increasingly used to select patients for molecular radiotherapy, guide EBRT boost volumes, monitor receptor occupancy, and personalize activity prescription. Combined modality approaches-such as EBRT plus PSMA-RLT in prostate cancer or EBRT plus SSTR-RLT in neuroendocrine tumors-are supported by biological rationales involving synergy between external and internal radiation sources. Adaptive strategies based on mid-treatment PET show promise in improving local control while minimizing toxicity. This review summarizes the current landscape and emerging applications of PET-guided therapy, highlighting methodological synergies between EBRT and RPT, strategies for treatment sequencing, biological dose painting, and adaptive therapy. It provides practical recommendations for implementing PET-guided workflows and discusses advances in radiobiology-informed dosimetry, whole-body PET technologies, and novel imaging biomarkers, including fibroblast activation protein inhibitors (FAPI), as key drivers of innovation. As PET technology evolves toward ultra-low-dose, ultra-fast total-body systems, the role of molecular imaging in therapeutic decision-making is expected to expand, ushering in a new era of biologically guided radiation oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.